NMBio MemberBiophagy, LLC

Biophagy’s corporate mission is to identify drugs that modulate autophagy as part of a specific disease process.

In so doing we hope to relieve patient symptoms or halt disease progression in therapeutic areas with high unmet need. Biophagy anticipates that new therapeutic entities (NTEs), e.g., repurposed drugs, or new chemical entities (NCEs) identified through its proprietary technologies can act alone or as adjunct therapy with standard medical protocols.

The company expects to amass a significant portfolio of intellectual property, to develop companion diagnostics for personalized medicine, and to become a world leader in bringing autophagy modulators to the marketplace in several important therapeutic areas.


Company/Organization Contacts

Ortner, Mary, President & CEO

Email | 505-200-9514


5901 Indian School Road NE
Albuquerque, NM 87110
Member Website»

Novo Norodisk

Novo Norodisk

Southwest Labs

Southwest Labs